309 results
8-K
INVA
Innoviva Inc
14 Dec 20
Entry into a Material Definitive Agreement
6:05am
the execution of its strategy and enhance returns on its capital. The partnership comprises (i) a strategic advisory agreement, pursuant to which … and subject to the terms set forth therein Sarissa Capital will assist Innoviva in the development of its acquisition strategy and (ii) an investment
8-K
EX-99.1
INVA
Innoviva Inc
14 Sep 22
Regulation FD Disclosure
5:22pm
that are not of historical fact, including, without limitation, statements regarding our strategy, future operations, future financial position, future revenue, projected … and objectives (related to our growth strategy and corporate development initiatives beyond our existing portfolio); the timing, manner and amount
8-K
EX-99.2
INVA
Innoviva Inc
26 May 20
Departure of Directors or Certain Officers
5:14pm
strategy and focus on value creation for shareholders
BURLINGAME, Calif.--(BUSINESS WIRE)--May 21, 2020-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva … with a strong background in strategy, business development and corporate finance and has focused much of his career on the creation of significant
8-K
EX-99.1
INVA
Innoviva Inc
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
Intended to Accelerate Capital Return Strategy for Proposed Royalty Management Company —
SOUTH SAN FRANCISCO, CA, April 21, 2014 — Theravance, Inc. (NASDAQ … . The net proceeds from this transaction are currently planned to support the initiation of a capital return strategy to the stockholders of Theravance
8-K
EX-99.1
INVA
Innoviva Inc
7 Apr 22
Regulation FD Disclosure
5:09pm
. All statements contained herein that are not of historical fact, including, without limitation, statements regarding our strategy, future operations … and by other pharmaceutical companies; our strategies, plans and objectives (related to our growth strategy and corporate development initiatives beyond our
8-K
EX-99
vj5172vv i783xk
26 Feb 09
Regulation FD Disclosure
12:00am
8-K
EX-99.2
lz9suulgs3i dsvge
25 Apr 13
Regulation FD Disclosure
12:00am
8-K
EX-99.1
12v6dbli e6zjv
25 Aug 23
Innoviva Appoints Stephen Basso as Chief Financial Officer
5:24pm
8-K
EX-99.1
vq0 3sujgdtw
13 Dec 21
Corporate Presentation December 2021
4:39pm
8-K
EX-99.1
y2lfip6ucf gb
3 Feb 21
Innoviva Reports Fourth Quarter 2020 Financial Results
5:14pm
8-K
EX-99.1
1o62hz4wv4 vm
29 Feb 24
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
4:15pm
SC TO-C
EX-99.3
olfva3zxufp8bnk 1u
23 May 22
Information about tender offer
8:54pm
8-K
EX-99.1
7e0j9ct8ily9r2
8 May 24
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
4:44pm
8-K
EX-99.1
4zc11dgo5hvlt
9 Nov 22
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
4:17pm
8-K
EX-99.1
n85p febki4ytq
28 Apr 23
Innoviva Announces Retirement of Board Chairman
8:30pm
8-K
EX-99.1
21istujuf1z
20 May 21
Innoviva Announces Strategic Repurchase of GSK’s Equity Stake
5:12pm
DEFA14A
3adyj4zt 9a
28 Apr 23
Additional proxy soliciting materials
8:38pm
8-K
EX-99
brinsb8bbgedb2r
29 Jun 07
Other Events
12:00am
8-K
EX-99
q0w14kcg9zr z616nzu8
19 Nov 08
Regulation FD Disclosure
12:00am
8-K
EX-99.1
a6tepuvmm84
13 Jul 12
Other Events
12:00am